Compare BY & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | NNNN |
|---|---|---|
| Founded | 1914 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | 2025 |
| Metric | BY | NNNN |
|---|---|---|
| Price | $29.52 | $32.39 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $33.67 | N/A |
| AVG Volume (30 Days) | ★ 196.7K | 37.8K |
| Earning Date | 01-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 1.54 | N/A |
| EPS | ★ 2.80 | 0.06 |
| Revenue | ★ $400,663,000.00 | $8,185,146.00 |
| Revenue This Year | $19.64 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | ★ $10.61 | $619.66 |
| Revenue Growth | 7.23 | ★ 21.95 |
| 52 Week Low | $22.63 | $5.18 |
| 52 Week High | $31.24 | $55.65 |
| Indicator | BY | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 52.88 |
| Support Level | $29.72 | $31.18 |
| Resistance Level | $31.00 | $38.00 |
| Average True Range (ATR) | 0.54 | 4.77 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 11.63 | 38.83 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.